Technical Notes Covering Pharma Equities - AbbVie, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, and Teva Pharma Industries

Editor Note: For more information about this release, please scroll to bottom.

LONDON, November 6, 2014 /PRNewswire/ --

Investor-Edge has initiated coverage on the following equities: AbbVie Inc. (NYSE: ABBV), Bristol-Myers Squibb Company (NYSE: BMY), GlaxoSmithKline PLC (NYSE: GSK), Eli Lilly and Company (NYSE: LLY), and Teva Pharmaceutical Industries Ltd (NYSE: TEVA). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Wednesday, November 05, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,484.53, up 0.58% and the NASDAQ Composite closed at 4,620.72, down 0.06%. The S&P 500 finished the session 0.57% higher at 2,023.57. During the trading session, nine out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index ended the day at 778.22, down 0.19%, whereas the index has gained 10.98% in the previous three months. Register for your complimentary reports on these five stocks at:  

http://investor-edge.com/register

AbbVie Inc.'s stock edged 0.19% lower, to close the day at $62.54. The stock recorded a trading volume of 6.46 million shares, much below its three months average volume of 14.05 million shares. The company's shares oscillated between $62.20 and $63.67 during the session. Over the last one month and over the past three months, AbbVie Inc.'s shares have gained 6.56% and 18.47%, respectively. Further, the stock has advanced 18.42% since the start of this year. The company's stock is trading above its 50-day and 200-day moving averages. The stock's 50-day moving average of $57.57 is above its 200-day moving average of $53.64. Additionally, the stock traded at a PE ratio of 21.24 and has a Relative Strength Index (RSI) of 65.29. Sign up and read the free notes on ABBV at:

www.Investor-Edge.com/ABBV-06Nov2014

On Wednesday, shares in Bristol-Myers Squibb Co. recorded a trading volume of 4.62 million shares, lower than its three months average volume of 6.31 million shares. The stock ended the day at $57.82, which was 0.03% below its previous day's closing of $57.84, and registered an intraday range of $57.38 and $58.34. Shares of the company traded at a PE ratio of 34.06. Bristol-Myers Squibb Co.'s stock has gained 13.71% in the last one month, 17.14% in the previous three months, and 8.79% on YTD basis. The company's stock is trading above its 50-day and 200-day moving averages of $51.56 and $50.74, respectively. Furthermore, shares of Bristol-Myers Squibb Co. have an RSI of 74.06. The complimentary notes on BMY can be downloaded as in PDF format at:

www.Investor-Edge.com/BMY-06Nov2014

GlaxoSmithKline PLC's stock edged 0.43% higher to end Wednesday's session at $45.14. The stock recorded a trading volume of 3.58 million shares, below its three months average volume of 5.00 million shares. The company's shares fluctuated between $45.08 and $45.47 during the session. GlaxoSmithKline PLC's shares have lost 15.45% since the beginning of 2014. Further, the stock has fallen by 0.77% in the previous three trading sessions and 1.31% over the last one month. The company's stock is trading below its 50-day and 200-day moving averages. The stock's 200-day moving average of $51.39 is above its 50-day moving average of $46.11. Additionally, the stock has an RSI of 53.53. Register for free on Investor-Edge and access the latest research on GSK at:

www.Investor-Edge.com/GSK-06Nov2014

On Wednesday, shares in Eli Lilly and Co. fluctuated between $66.76 and $67.61 before ending the session 0.27% lower at $66.99. The stock reported a trading volume of 3.04 million shares, lower than its three months average volume of 3.94 million shares. Shares of the company traded at a PE ratio of 25.84. Eli Lilly and Co.'s shares have advanced 1.00% in the previous three trading sessions, 2.01% in the last one month, and 31.35% on YTD basis. The company's stock is trading above its 50-day and 200-day moving averages of $64.85 and $60.76, respectively. Moreover, shares of Eli Lilly and Co. have an RSI of 62.54. The complete research on LLY is available for free at:

www.Investor-Edge.com/LLY-06Nov2014

Shares in Teva Pharmaceutical Industries Ltd finished Wednesday's session 0.34% lower at $57.79. A total of 4.54 million shares were traded, which was above its three months average volume of 3.90 million shares. The stock vacillated between $57.63 and $58.13 during the session. Over the last one month and over the past three months, Teva Pharmaceutical Industries Ltd's shares have advanced 5.21% and 9.49%, respectively. Additionally, from the beginning of 2014, the stock has gained an upside of 44.19%. The company's shares are trading above their 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $52.89 is greater than its 200-day moving average of $51.09. Teva Pharmaceutical Industries Ltd's stock has an RSI of 72.06. Free in depth research on TEVA is available at:

www.Investor-Edge.com/TEVA-06Nov2014

About Investor-Edge.com 

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


SOURCE Investor-Edge

Suggested Articles

Talk about making pharma history. Merck's Keytruda has racked up yet another first-of-its-kind approval, this time in a combo with Eisai’s Lenvima.

In an era of limited access to key decision makers, how are you mobilizing your field force to communicate the value of your brands and real-world evidence?

Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.